Pharmacology 514:
Current Topics in Pharmacology
Journal Club




Instructions for

JClub Archive

Current Topics in Pharmacology
Phcol 514
12:30 PM, Wednesday, April 14, 1999
Room T-530/530A HSC

Speaker: Kevin White
Topic: From the South Pacific to Germany: Kava-Kava makes its debut as an anti-anxiety drug


  1. Magura EI, Kopanitsa MV, Gleitz J, Peters T, and Krishtal OA. (1997). Kava extract ingredients, (+)-methysticin and (+/-)-kavain inhibit voltage-operated Na+-channels in rat CA1 hippocampal neurons. Neuroscience. 81:345-351.

  2. Gleitz J, et al. (1996). Kavain inhibits non-stereospecifically veratidine-activated Na+ channels. Planta Medica. 62:580-581.

  3. Gleitz J, Friese J, Beile A, Ameri A, and Peters T. (1996). Aniconvulsive action of (+/-) kavain estimated from its properties on stimulated synaptomsomes and Na+ channel receptor sites. European Journal of Pharmacology. 315:89-97.

  4. Gleitz J and Friese J (1998). Kavain, dihydrokavain and dihydromethysticin non-competitively inhibit the specific binding of [3H]-batrachotoxin-A 20-a-benzoate to receptor site 2 of voltage-gated Na+ channels. Planta Medica. 64:458-459.

  5. Boonen G and Haberlein H (1998). Influence of genuine kavapyrone enantiomers on the GABAA binding site. Planta Medica. 64:504-506.

  6. Seitz U, Schule A, and Gleitze J. (1997). [3H]-Monoamine uptake inhibition properties of kava pyrones. Planta Medica. 63:548-549.

  7. Uebelhack R, Franke L, and Schewe HJ. (1998). Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum forster (kava-kava). Pharmacopsychiatry. 31:187-192.

  8. Boonen G, Ferger B, Kuschinsky K, and Haberlein H. (1998). In vivo effects of the kavapyrones (+)-dihydromethysticin and (+/-)-kavain on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions. Planta Medica. 64:507-510.

  9. Baum SS, Hill R, and Rommelspacher H. (1998). Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog. Neuro-Psychopharmacol. and Biol. Psychiat. 22:1105-1120.

  10. Schirrmacher K, Busselberg D, Langosch JM, Walden J, Winter U, and Bingmann D. (1999). Effects of (+/-)-kavain on voltage-activated inward currents of dorsal root ganglion cells from neonatal rats. European Neuropsychopharmacology. 9:171-176.

  11. Langosch JM, Normann C, Schirrmacher K, Berger M, and Walden J. (1998). The influence of (+/-)-kavain on population spikes and long-term potentiation in guinea pig hippocampal slices. Comparative Biochemistry and Physiology Part A. 120:545-549.

  12. Walden J, Von Wegerer J, Winter U, Berger M, and Grunze H. (1997). Effects of Kawain and dihydromethysticin on field potential changes in the hippocampus. Prog. Neuro-Psychopharmacol. and Biol. Psychiat. 21:697-706.

  13. Walden J, et al. (1997). Actions of kavain and dihydromethysticin on ipsaparone-induced field potential changes in the hippocampus. Human Psychopharmacology. 12:265-270.

  14. Foo H and Lemon J. (1997). Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug and Alcohol review. 16:147-155.

  15. Voltz H.P and Kieser M. (1997). Kava-kava extract WS 1490 versus placebo in anxiety disorders-a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiat. 30:1-5.

1998-1999 Journal Club Archive

Announcements | Schedule | Faculty | Instructions for Speakers | JClub Archives